Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/07/071051
CTRI/2024/07/071051
Not yet recruiting
Phase 2

ow dose Nivolumab in combination with Neoadjuvant Chemotherapy followed by concurrent Chemoradiation in advanced Carcinoma Cervix: A phase II study - NI

ICMR0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified
Sponsor
ICMR
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
ICMR

Eligibility Criteria

Inclusion Criteria

  • •1 Histologically confirmed FIGO stage IIIC\-IVa squamous, adeno or adenosquamous carcinoma of the cervix
  • •2 Deemed suitable and fit for radical chemoradiation.
  • •3 Medically fit to receive carboplatin and paclitaxel.
  • •4 ECOG performance status 0 – 1
  • •5 Aged 18 and over

Exclusion Criteria

  • •1 Presence of locally advanced disease who is not fit for radical chemoradiation
  • •2 Participants with more than or equal to Grade 2 peripheral neuropathy
  • •3 Participants with an active, known or suspected autoimmune disease
  • •4 Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of enrollment
  • •5 Known history of positive test for human immunodeficiency virus or known acquired immunodeficiency syndrome

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 2
Evaluation of low dose immunotherapy for lung cancer
CTRI/2023/02/050126Indian Council of Medical Research
Completed
Phase 3
CheckMate 816: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 816on-Small Cell Lung Cancer
JPRN-jRCT2080223597Bristol-Myers Squibb K.K.642
Withdrawn
Not Applicable
A Phase II Study of Nivolumab in Combination with Radiation Therapy as Definitive Treatment for Patients with Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
KCT0004049Samsung Medical Center26
Recruiting
Phase 2
eo-adjuvant T-VEC + Nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease.
NL-OMON49074Antoni van Leeuwenhoek Ziekenhuis24
Active, not recruiting
Phase 1
A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinomaThoracic esophageal cancer
JPRN-jRCT2031180172Kato Ken36